About this Journal Submit a Manuscript Table of Contents 
Abstract and Applied Analysis
Volume 2012 (2012), Article ID 590326, 13 pages
doi:10.1155/2012/590326
Research Article

Analysis of Wave Solutions of an Adhenovirus-Tumor Cell System

Baba Issa Camara1 and Houda Mokrani2

1Laboratoire des Interactions Ecotoxicologie, Biodiversité, Ecosystèmes, Université de Lorraine, CNRS UMR 7146, 8 rue du Général Delestraint, 57070 METZ, France
2Laboratoire de Mathématiques Raphaël Salem, Université de Rouen, UMR 6085 CNRS, Avenue de l'Université, P.O. Box 12, 76801 Saint Etienne du Rouvray, France

Received 2 December 2011; Accepted 13 February 2012

Academic Editor: Muhammad Aslam Noor

Copyright © 2012 Baba Issa Camara and Houda Mokrani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Claes, A. J. Idema, and P. Wesseling, “Diffuse glioma growth: a guerilla war,” Acta Neuropathologica, vol. 114, no. 5, pp. 443–458, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. R. Bischoff, D. H. Kirn, A. Williams et al., “An adenovirus mutant that replicates selectively in p53-deficient human tumor cells,” Science, vol. 274, no. 5286, pp. 373–376, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff, and D. H. Kirn, “ONYX-015, an E1b gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents,” Nature Medicine, vol. 3, no. 6, pp. 639–645, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. E. A. Chiocca, K. M. Abbed, S. Tatter et al., “A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting,” Molecular Therapy, vol. 10, no. 5, pp. 958–966, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. N. L. Komarova, “Mathematical modeling of tumorigenesis: mission possible,” Current Opinion in Oncology, vol. 17, no. 1, pp. 39–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. S. Novozhilov, F. S. Berezovskaya, E. V. Koonin, and G. P. Karev, “Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models,” Biology Direct, vol. 1, article no. 6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. T. Oden, A. Hawkins, and S. Prudhomme, “General diffuse-interface theories and an approach to predictive tumor growth modeling,” Mathematical Models & Methods in Applied Sciences, vol. 20, no. 3, pp. 477–517, 2010. View at Publisher · View at Google Scholar · View at Zentralblatt MATH
  8. D. Wodarz, “Viruses as antitumor weapons: defining conditions for tumor remission,” Cancer Research, vol. 61, no. 8, pp. 3501–3507, 2001. View at Scopus
  9. D. Wodarz and N. Komarova, Computational Biology of Cancer: Lecture Notes And Mathematical Modelin, World Scientific, Singapour, 2005.
  10. B. I. Camara, H. Mokrani, and E. Afenya, “Mathematical modelling of gliomas therapy using oncolytic viruses,” to appear.
  11. W. Walter, “Differential inequalities and maximum principles: theory, new methods and applications,” vol. 30, no. 8, pp. 4695–4711, 1997. View at Publisher · View at Google Scholar
  12. H. L. Smith, “Dynamics of competition,” in Mathematics Inspired by Biology, vol. 1714 of Lecture Notes in Math., pp. 191–240, Springer, Berlin, Germany, 1999. View at Zentralblatt MATH